Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, Hafner R, Bassily EL, Lederman HM, Knirsch C, Benson CA, Valdez H, Aberg JA, McCutchan JA. Currier JS, et al. Ann Intern Med. 2000 Oct 3;133(7):493-503. doi: 10.7326/0003-4819-133-7-200010030-00008. Ann Intern Med. 2000. PMID: 11015162 Clinical Trial.
A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l.
Koletar SL, Heald AE, Finkelstein D, Hafner R, Currier JS, McCutchan JA, Vallee M, Torriani FJ, Powderly WG, Fass RJ, Murphy RL; ACTG 888 Study Team. Koletar SL, et al. Among authors: currier js. AIDS. 2001 Aug 17;15(12):1509-15. doi: 10.1097/00002030-200108170-00008. AIDS. 2001. PMID: 11504983 Clinical Trial.
Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infection.
von Reyn CF, Williams PL, Lederman HM, McCutchan JA, Koletar SL, Murphy RL, Cohn SE, Evans T, Heald AE, Colquhoun D, Bassily EL, Currier JS. von Reyn CF, et al. Among authors: currier js. Clin Diagn Lab Immunol. 2001 Nov;8(6):1277-8. doi: 10.1128/CDLI.8.6.1277-1278.2001. Clin Diagn Lab Immunol. 2001. PMID: 11687476 Free PMC article.
Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.
Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team. Lennox JL, et al. Among authors: currier js. Ann Intern Med. 2014 Oct 7;161(7):I-22. doi: 10.7326/P14-9035. Ann Intern Med. 2014. PMID: 25285557 Free article. No abstract available.
A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team.
Parenti DM, Williams PL, Hafner R, Jacobs MR, Hojczyk P, Hooton TM, Barber TW, Simpson G, van der Horst C, Currier J, Powderly WG, Limjoco M, Ellner JJ. Parenti DM, et al. AIDS. 1998 Dec 24;12(18):2439-46. doi: 10.1097/00002030-199818000-00013. AIDS. 1998. PMID: 9875582 Clinical Trial.
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group. Priddy FH, et al. Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993. Clin Infect Dis. 2008. PMID: 18433307 Clinical Trial.
325 results